Insights from the 2024 recruitment phase revealed several opportunities to refine our approach for accelerating enrolment in 2025. Key improvements include adjustments to the inclusion/exclusion criteria and the addition of new recruitment sites.
....on track to reach its interim analysis in 2025
The Company has been engaged in licensing negotiations that would provide the capital necessary to continue the current Phase III clinical trial. These conversations are anticipated to conclude in early 2025.
…the Company is comfortable that it will secure a partner for its R&D program. In addition, the R&D spend made at the conclusion of 2024 is eligible for a further loan from Endpoint Capital to provide the Company’s tax reimbursement early.
AVE Price at posting:
0.4¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)